5 tests/box, 25 tests/box, 40 tests/box, 100 tests/box
Certificates: CE, SGS ISO13485, ISO9001
Matching Equipments: Solid Phase Fluorescence Immunoassay System Manufactured by Guangzhou KOFA Biotechnology Co.,Ltd.
Intended Use: This reagent kit is base on fluorescent chromatographic technology, supporting the quantitative rapid test of Myo level in the serum/plasma, and Myo is the sensitive indicator for the early acute myocardial infraction (AMI)
The advantages of KOFA Myo
1. Advanced fluoroimmunoassay quantitative testing platform, make accurate and quantitative rapid test of Myo level available
2. Low cost and rapid test, can get the quantitative and reliable results in 15minutes, shorten the testing turnaround time.
3. The testing results from KOFA Myo has good correlation with that of Roche diagnostics (compared with thousands of cases)
4. Simple operation and rapid test, can meet the need of various departments.
5. The combined detection of Myo, cTnI and CK-MB contributes to the early diagnosis of acute myocardial infraction, AMI.
Applicable Departmets: Departments of cardiology, surgery, geriatrics respiratory emergency ward and ICU.